Show simple item record

dc.contributor.authorBeykou, M
dc.contributor.authorArias-Garcia, M
dc.contributor.authorRoumeliotis, TI
dc.contributor.authorChoudhary, JS
dc.contributor.authorMoser, N
dc.contributor.authorGeorgiou, P
dc.contributor.authorBakal, C
dc.coverage.spatialEngland
dc.date.accessioned2022-09-15T14:27:11Z
dc.date.available2022-09-15T14:27:11Z
dc.date.issued2022-07-11
dc.identifierARTN 395
dc.identifier10.1038/s41597-022-01512-1
dc.identifier.citationScientific Data, 2022, 9 (1), pp. 395 -
dc.identifier.issn2052-4463
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/5489
dc.identifier.eissn2052-4463
dc.identifier.eissn2052-4463
dc.identifier.doi10.1038/s41597-022-01512-1
dc.description.abstractWhen used in combination with hormone treatment, Palbociclib prolongs progression-free survival of patients with hormone receptor positive breast cancer. Mechanistically, Palbociclib inhibits CDK4/6 activity but the basis for differing sensitivity of cancer to Palbociclib is poorly understood. A common observation in a subset of Triple Negative Breast Cancers (TNBCs) is that prolonged CDK4/6 inhibition can engage a senescence-like state where cells exit the cell cycle, whilst, remaining metabolically active. To better understand the senescence-like cell state which arises after Palbociclib treatment we used mass spectrometry to quantify the proteome, phosphoproteome, and secretome of Palbociclib-treated MDA-MB-231 TNBC cells. We observed altered levels of cell cycle regulators, immune response, and key senescence markers upon Palbociclib treatment. These datasets provide a starting point for the derivation of biomarkers which could inform the future use CDK4/6 inhibitors in TNBC subtypes and guide the development of potential combination therapies.
dc.formatElectronic
dc.format.extent395 -
dc.languageeng
dc.language.isoeng
dc.publisherNATURE PORTFOLIO
dc.relation.ispartofScientific Data
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectCyclin-Dependent Kinase 4
dc.subjectCyclin-Dependent Kinase 6
dc.subjectFemale
dc.subjectHumans
dc.subjectProteome
dc.subjectProteomics
dc.subjectTriple Negative Breast Neoplasms
dc.titleProteomic characterisation of triple negative breast cancer cells following CDK4/6 inhibition.
dc.typeJournal Article
dcterms.dateAccepted2022-06-28
dc.date.updated2022-09-15T14:26:50Z
rioxxterms.versionVoR
rioxxterms.versionofrecord10.1038/s41597-022-01512-1
rioxxterms.licenseref.startdate2022-07-11
rioxxterms.typeJournal Article/Review
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/35817775
pubs.issue1
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology/Dynamical Cell Systems
pubs.organisational-group/ICR/ImmNet
pubs.publication-statusPublished online
pubs.publisher-urlhttp://dx.doi.org/10.1038/s41597-022-01512-1
pubs.volume9
icr.researchteamProte & Metabolomics Fac
icr.researchteamDynamical Cell Systems
dc.contributor.icrauthorRoumeliotis, Theodoros
dc.contributor.icrauthorChoudhary, Jyoti
dc.contributor.icrauthorBakal, Christopher
icr.provenanceDeposited by Mr Arek Surman on 2022-09-15. Deposit type is initial. No. of files: 1. Files: Proteomic characterisation of triple negative breast cancer cells following CDK46 inhibition.pdf


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/